ClinicalTrials.gg
CompletedNCT02309411EINSTEINJrUpdated Aug 21, 2018Results posted

EINSTEIN Junior Phase II: Oral Rivaroxaban in Young Children With Venous Thrombosis

A Phase 2 interventional study of Rivaroxaban (Xarelto, BAY59-7939) in Venous Thromboembolism, sponsored by Bayer. Completed at 29 sites in 15 countries. Open to participants aged 6 Months to 5 Years. Per ClinicalTrials.gov, last updated 2018-08-21.

Sponsored by Bayer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
46
Allocation
Not applicable
Ages
6 Months to 5 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 61 studies testing rivaroxaban in Venous Thromboembolism — 18 open to participants now, 18 under way, 6 of them phase 3. Rivaroxaban · Venous Thromboembolism.

Enrollment
52nd of 61
46 · median 272
Started
2015
with 1 other
Phase 2
9 of 61
none open now
Registered
21st of 61
by date
Lead sponsor
15 of 61
Bayer

Among the 61 studies testing rivaroxaban in Venous Thromboembolism, this one is the 52nd largest by enrollment, is one of 2 that started in 2015, is one of 9 in phase 2, and was the 21st registered.

Venous Thromboembolism

713 studies on the registry are indexed under Venous Thromboembolism; 147 are open to participants now.

Browse Venous Thromboembolism studies →

Open to participants now

18 of the 61 studies testing rivaroxaban in Venous Thromboembolism are open now, in 12 countries. Recruiting first, the newest first:

13 more — sign in →

By country, each count listing its studies:

All 18 open studies →

About rivaroxaban

Rivaroxaban: first FDA approval 2011 (XARELTO), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 113 Venous Thromboembolism studies recruiting now, 90 (80%) set no upper age limit and 13 (12%) stop at 75 or younger; 9 take children under 18; 10 take healthy volunteers.

This study: 6 Months to 5 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 61 studies testing rivaroxaban in Venous Thromboembolism, or all of them as a file.
02

Study summary

The purpose of this study is to find out whether rivaroxaban is safe to use in children and how long it stays in the body. Safety will be assessed by looking at the incidence and types of bleeding events. There will also be a check for worsening of blood clots.

03

Conditions studied

  • Venous Thromboembolism

Keywords

  • Pediatric
04

Who can participate

Ages eligible
6 Months to 5 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children aged 6 months to \< 6 years who have been treated for at least 2 months or, in case of catheter related thrombosis, for at least 6 weeks with LMWH (low molecular weight heparin), fondaparinux and/or VKA (vitamin K antagonist) for documented symptomatic or asymptomatic venous thrombosis - , , creatinine, (ALT) and evaluated within 10 days prior to randomization
  • provided

Exclusion criteria

Exclusion Criteria:

  • Active bleeding or high risk for bleeding contraindicating anticoagulant therapy
  • Symptomatic progression of venous thrombosis during preceding anticoagulant treatment
  • Planned invasive procedures, including lumbar puncture and removal of non peripherally placed central lines during study treatment
  • An estimated (eGFR) \< 30 mL/min/1.73 m\^2
  • Hepatic disease which is associated with either: coagulopathy leading to a bleeding risk, or > 5x upper level of normal () or total > 2x ULN with direct bilirubin > 20% of the total
  • count \< 50 x 10*9/L
  • Hypertension defined as > 95th age percentile
  • \< 3 months
  • Concomitant use of strong inhibitors of both cytochrome P450 isoenzyme 3A4 () and P-glycoprotein (P-gp), i.e. all protease inhibitors and the following azole antimycotics agents: ketoconazole, itraconazole, voriconazole, posaconazole, if used systemically
  • Concomitant use of strong inducers of CYP3A4, i.e. rifampicin, rifabutin, phenobarbital, phenytoin and carbamazepine
  • or any other listed in the local labeling for the comparator treatment or experimental treatment
  • Inability to cooperate with the study procedures
  • Previous randomization to this study
  • Participation in a study with an drug or medical device within 30 days prior to randomization
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
46 participants (actual)

Study arms

  • Experimental
    Rivaroxaban

    Age and body weight-adjusted twice daily dosing of rivaroxaban to achieve a similar exposure as that observed in adults treated for venous thromboembolism (VTE) with 20 mg rivaroxaban once daily

    Drug: Rivaroxaban (Xarelto, BAY59-7939)

Interventions

  • With age and body-weight adjusted twice daily dosing of rivaroxaban as Oral Suspension to achieve a similar exposure as that observed in adults treated with 20 mg rivaroxaban once daily, and no other anticoagulant

06

What researchers measure

Primary outcomes

  1. Number of Subjects With Major Bleeding and Clinically Relevant Non-Major Bleeding Events

    Major bleeding is defined as overt bleeding and: * associated with a fall in hemoglobin of 2 gram/decilitre (g/dL) or more, or * leading to a transfusion of the equivalent of 2 or more units of packed red blood cells or whole blood in adults, or * occurring in a critical site, for example (e.g.) intracranial, intraspinal, intraocular, pericardial, intraarticular, intramuscular with compartment syndrome, retroperitoneal, or * contributing to death. Clinically relevant non-major bleeding is defined as overt bleeding not meeting the criteria for major bleeding, but associated with: * medical intervention, or * unscheduled contact (visit or telephone call) with a physician, or * cessation (temporary) of study treatment, or * discomfort for the child such as pain or * impairment of activities of daily life (such as loss of school days or hospitalization).

    Time frame: During or within 2 days after stop of study treatment (up to 32 days)

Secondary outcomes

  1. Number of Subjects With Symptomatic Recurrent Venous Thromboembolism

    Venous thromboembolism is the formation of a blood clot (thrombus) inside a blood vessel, obstructing the flow of blood through the circulatory system. The occurrence of recurrent venous thromboembolism was summarized by age group. Symptomatic recurrence, which is the composite of deep Vein Thrombosis (DVT), non-fatal Pulmonary Embolism (PE), and fatal PE of venous thrombosis, had to be documented using appropriate (repeat) imaging test.

    Time frame: From start of the study treatment up to 30-days post study treatment period (approximately 60 days)

  2. Number of Subjects With Asymptomatic Deterioration in Thrombotic Burden on Repeat Imaging

    The occurrence of asymptomatic deterioration in thrombotic burden was summarized by age group. At the end of the 30-day treatment period, a repeat imaging of the thrombus was performed. The images of the index event and repeat imaging were adjudicated by the central independent adjudication committee (CIAC). The thrombotic burden at the time of the index event was compared to the thrombotic burden at the time of repeat imaging. The outcome of the adjudication was classified as normalized, improved, no relevant change, deteriorated, or not evaluable. Due to missing repeated imaging, thrombotic burden assessments were not done in some subjects.

    Time frame: At the end of the 30-day treatment period

  3. Change From Baseline in Prothrombin Time at Specified Time Points

    Prothrombin time is a global clotting test used for the assessment of the extrinsic pathway of the blood coagulation cascade. Day 30 (10-16 hours post-dose) was considered as a baseline.

    Time frame: Day 1 (2.5-4 hours post-dose); Day 15 (2-8 hours post-dose); Day 30 (10-16 hours post-dose)

  4. Change From Baseline in Activated Partial Thromboplastin Time at Specified Time Points

    The Activated partial thromboplastin time (aPTT) is a screening test for the intrinsic pathway. Day 30 (10-16 hours post-dose) was considered as a baseline.

    Time frame: Day 1 (2.5-4 hours post-dose); Day 15 (2-8 hours post-dose); Day 30 (10-16 hours post-dose)

  5. Concentration of Rivaroxaban in Plasma as a Measure of Pharmacokinetics at Specified Time Points

    Concentration of rivaroxaban in plasma was measured at Day 1, 15 and 30 at specified time points. In the below table, 'n' signifies those subjects who were evaluable for this measure at given time points for each group. Geometric mean and percentage geometric coefficient of variation (%CV) were reported.

    Time frame: Day 1 (30-90 minutes, 2.5-4 hours post-dose); Day 15 (2-8 hours post-dose) and Day 30 (10-16 hours post-dose)

Other outcomes

  1. Anti-factor Xa Values at Specified Time Points

    The individual anti-Factor Xa activity was determined ex-vivo using a photometric method. The anti-factor Xa assay is designed to measure plasma heparin, low molecular weight heparin and other anticoagulants. In the below table, 'n' signifies those subjects who were evaluable for this measure at given time points for each group.

    Time frame: Day 1 (2.5-4 hours post-dose); Day 15 (2-8 hours post-dose) and Day 30 (10-16 hours post-dose)

07

Results

Posted Jun 13, 2018
Limitations and caveats
Study started as randomized but the Comparator arm sample size was too small for meaningful comparison; it was removed in Protocol amendment and approved by review board. Results only reported for rivaroxaban arm as single arm study.

Participant flow

Study was conducted at 27 study centers in 14 countries: Australia, Austria, Brazil, Canada, Hungary, Israel, Italy, Japan, Netherlands, Russia, Spain, Switzerland, United Kingdom, and United States between 15 January 2015 (first subject first visit) and 05 April 2017 (last subject last visit).

Participant flow — Overall Study
MilestoneRivaroxaban, Suspension, BID, Age: 2-6 YearsRivaroxaban Suspension, BID, Age: 6 Months-2 YearsAnticoagulants, Comparator, Age: 2-6 Years
Started25156
Completed23146
Not completed210
Withdrew: Physician decision100
Withdrew: Withdrawal by subject110

Outcome measures

PrimaryNumber of Subjects With Major Bleeding and Clinically Relevant Non-Major Bleeding Events

Major bleeding is defined as overt bleeding and: * associated with a fall in hemoglobin of 2 gram/decilitre (g/dL) or more, or * leading to a transfusion of the equivalent of 2 or more units of packed red blood cells or whole blood in adults, or * occurring in a critical site, for example (e.g.) intracranial, intraspinal, intraocular, pericardial, intraarticular, intramuscular with compartment syndrome, retroperitoneal, or * contributing to death. Clinically relevant non-major bleeding is defined as overt bleeding not meeting the criteria for major bleeding, but associated with: * medical intervention, or * unscheduled contact (visit or telephone call) with a physician, or * cessation (temporary) of study treatment, or * discomfort for the child such as pain or * impairment of activities of daily life (such as loss of school days or hospitalization).

Time frame:
During or within 2 days after stop of study treatment (up to 32 days)
Reported as:
Count of participants · Participants
Number of Subjects With Major Bleeding and Clinically Relevant Non-Major Bleeding Events
ParticipantsRivaroxaban, Suspension, BID, Age: 2-6 YearsRivaroxaban Suspension, BID, Age: 6 Months-2 Years
Major bleeding events00
Clinically relevant non-major bleeding events00
SecondaryNumber of Subjects With Symptomatic Recurrent Venous Thromboembolism

Venous thromboembolism is the formation of a blood clot (thrombus) inside a blood vessel, obstructing the flow of blood through the circulatory system. The occurrence of recurrent venous thromboembolism was summarized by age group. Symptomatic recurrence, which is the composite of deep Vein Thrombosis (DVT), non-fatal Pulmonary Embolism (PE), and fatal PE of venous thrombosis, had to be documented using appropriate (repeat) imaging test.

Time frame:
From start of the study treatment up to 30-days post study treatment period (approximately 60 days)
Reported as:
Count of participants · Participants
Number of Subjects With Symptomatic Recurrent Venous Thromboembolism
ParticipantsRivaroxaban, Suspension, BID, Age: 2-6 YearsRivaroxaban Suspension, BID, Age: 6 Months-2 Years
Number of Subjects With Symptomatic Recurrent Venous Thromboembolism00
SecondaryNumber of Subjects With Asymptomatic Deterioration in Thrombotic Burden on Repeat Imaging

The occurrence of asymptomatic deterioration in thrombotic burden was summarized by age group. At the end of the 30-day treatment period, a repeat imaging of the thrombus was performed. The images of the index event and repeat imaging were adjudicated by the central independent adjudication committee (CIAC). The thrombotic burden at the time of the index event was compared to the thrombotic burden at the time of repeat imaging. The outcome of the adjudication was classified as normalized, improved, no relevant change, deteriorated, or not evaluable. Due to missing repeated imaging, thrombotic burden assessments were not done in some subjects.

Time frame:
At the end of the 30-day treatment period
Reported as:
Count of participants · Participants
Number of Subjects With Asymptomatic Deterioration in Thrombotic Burden on Repeat Imaging
ParticipantsRivaroxaban, Suspension, BID, Age: 2-6 YearsRivaroxaban Suspension, BID, Age: 6 Months-2 Years
Normalized64
Improved154
No relevant change13
Deteriorated00
Not evaluable00
Not available00
Missing34
SecondaryChange From Baseline in Prothrombin Time at Specified Time Points

Prothrombin time is a global clotting test used for the assessment of the extrinsic pathway of the blood coagulation cascade. Day 30 (10-16 hours post-dose) was considered as a baseline.

Time frame:
Day 1 (2.5-4 hours post-dose); Day 15 (2-8 hours post-dose); Day 30 (10-16 hours post-dose)
Reported as:
Mean · Seconds
Change From Baseline in Prothrombin Time at Specified Time Points
SecondsRivaroxaban, Suspension, BID, Age: 2-6 YearsRivaroxaban Suspension, BID, Age: 6 Months-2 Years
Day 1: 2.5-4 hours post-dose2.777 ± 4.8452.514 ± 3.53
Day 15: 2-8 hours post-dose2.586 ± 2.3874.764 ± 4.738
SecondaryChange From Baseline in Activated Partial Thromboplastin Time at Specified Time Points

The Activated partial thromboplastin time (aPTT) is a screening test for the intrinsic pathway. Day 30 (10-16 hours post-dose) was considered as a baseline.

Time frame:
Day 1 (2.5-4 hours post-dose); Day 15 (2-8 hours post-dose); Day 30 (10-16 hours post-dose)
Reported as:
Mean · Seconds
Change From Baseline in Activated Partial Thromboplastin Time at Specified Time Points
SecondsRivaroxaban, Suspension, BID, Age: 2-6 YearsRivaroxaban Suspension, BID, Age: 6 Months-2 Years
Day 1: 2.5-4 hours post-dose6.455 ± 17.036-3.479 ± 40.443
Day 15: 2-8 hours post-dose2.814 ± 6.37521 ± 66.761
SecondaryConcentration of Rivaroxaban in Plasma as a Measure of Pharmacokinetics at Specified Time Points

Concentration of rivaroxaban in plasma was measured at Day 1, 15 and 30 at specified time points. In the below table, 'n' signifies those subjects who were evaluable for this measure at given time points for each group. Geometric mean and percentage geometric coefficient of variation (%CV) were reported.

Time frame:
Day 1 (30-90 minutes, 2.5-4 hours post-dose); Day 15 (2-8 hours post-dose) and Day 30 (10-16 hours post-dose)
Reported as:
Geometric mean · microgram per liter (mcg/L)
Concentration of Rivaroxaban in Plasma as a Measure of Pharmacokinetics at Specified Time Points
microgram per liter (mcg/L)Rivaroxaban, Suspension, BID, Age: 2-6 YearsRivaroxaban Suspension, BID, Age: 6 Months-2 Years
Day 1: 30-90 minutes post-dose72.8494 ± 153.7668.0072 ± 160.77
Day 1: 2.5-4 hours post-dose108.6053 ± 58.1876.5371 ± 112.91
Day 15: 2-8 hours post-dose112.3578 ± 46.3761.3817 ± 451.46
Day 30: 10-16 hours post-dose19.8714 ± 189.495.9545 ± 354.51
Other pre-specifiedAnti-factor Xa Values at Specified Time Points

The individual anti-Factor Xa activity was determined ex-vivo using a photometric method. The anti-factor Xa assay is designed to measure plasma heparin, low molecular weight heparin and other anticoagulants. In the below table, 'n' signifies those subjects who were evaluable for this measure at given time points for each group.

Time frame:
Day 1 (2.5-4 hours post-dose); Day 15 (2-8 hours post-dose) and Day 30 (10-16 hours post-dose)
Reported as:
Mean · microgram per liter (mcg/L)
Anti-factor Xa Values at Specified Time Points
microgram per liter (mcg/L)Rivaroxaban, Suspension, BID, Age: 2-6 YearsRivaroxaban Suspension, BID, Age: 6 Months-2 Years
Day 1: 2.5-4 hours post-dose128.457 ± 69.61587.831 ± 84.178
Day 15: 2-8 hours post-dose103.105 ± 58.343131.369 ± 96.489
Day 30: 10-16 hours post-dose19.069 ± 17.46316.952 ± 19.725

Adverse events

Collected over From start of study drug administration until 30 day post study treatment (approximately 60 days). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rivaroxaban BID (Suspension) (2 - 6 Years Group)0/25 (0%)0/25 (0%)14/25 (56%)
Rivaroxaban BID (Suspension) (6 Months - 2 Years Group)0/15 (0%)2/15 (13.3%)11/15 (73.3%)
Anticoagulants, Comparator (2 - 6 Years Group)0/6 (0%)1/6 (16.7%)3/6 (50%)
Most frequent serious events
Most frequent serious events
EventRivaroxaban BID (Suspension) (2 - 6 Years Group)Rivaroxaban BID (Suspension) (6 Months - 2 Years Group)Anticoagulants, Comparator (2 - 6 Years Group)
Optic atrophyEye disorders0/250/151/6
HeadacheNervous system disorders0/250/151/6
PyrexiaGeneral disorders0/251/150/6
Respiratory disorderRespiratory, thoracic and mediastinal disorders0/251/150/6
Most frequent other events
Showing 10 of 69
Most frequent other events
EventRivaroxaban BID (Suspension) (2 - 6 Years Group)Rivaroxaban BID (Suspension) (6 Months - 2 Years Group)Anticoagulants, Comparator (2 - 6 Years Group)
Febrile neutropeniaBlood and lymphatic system disorders1/251/151/6
NeutropeniaBlood and lymphatic system disorders0/251/151/6
HaematocheziaGastrointestinal disorders0/250/151/6
Rectal haemorrhageGastrointestinal disorders0/250/151/6
GastroenteritisInfections and infestations0/250/151/6
Viral upper respiratory tract infectionInfections and infestations3/250/151/6
Blood fibrinogen decreasedInvestigations0/250/151/6
Platelet count decreasedInvestigations0/250/151/6
HypertriglyceridaemiaMetabolism and nutrition disorders0/250/151/6
HypoalbuminaemiaMetabolism and nutrition disorders0/250/151/6

Baseline characteristics

Age, Continuous
Age, Continuous(years)Rivaroxaban, Suspension, BID, Age: 2-6 YearsRivaroxaban Suspension, BID, Age: 6 Months-2 YearsAnticoagulants, Comparator, Age: 2-6 YearsTotal
Mean3.77 ± 1.031.26 ± 0.453.67 ± 0.822.94 ± 1.45
Sex: Female, Male
Sex: Female, Male(Participants)Rivaroxaban, Suspension, BID, Age: 2-6 YearsRivaroxaban Suspension, BID, Age: 6 Months-2 YearsAnticoagulants, Comparator, Age: 2-6 YearsTotal
Female129324
Male136322
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Rivaroxaban, Suspension, BID, Age: 2-6 YearsRivaroxaban Suspension, BID, Age: 6 Months-2 YearsAnticoagulants, Comparator, Age: 2-6 YearsTotal
American Indian or Alaska Native0000
Asian0101
Native Hawaiian or Other Pacific Islander0000
Black or African American1203
White2310639
More than one race0101
Unknown or Not Reported1102
08

Study locations

29 sites
  • Gainesville, Florida 32610, United States
  • Pensacola, Florida 32504, United States
  • Children's Healthcare of Atlanta
    Atlanta, Georgia 30322, United States
  • Chicago, Illinois 60611, United States
  • Indianapolis, Indiana 46202, United States
  • Parkville, Victoria 3052, Australia
  • Wien, 1090, Austria
  • São Paulo, Sao Paulo 01227-200, Brazil
  • São Paulo, Brazil
  • Toronto, Ontario M5G 1X8, Canada
  • Budapest, 1097, Hungary
  • Jerusalem, 9112001, Israel
  • Ramat Gan, 5262000, Israel
  • Milano, Lombardia 20122, Italy
  • Torino, Piemonte 10126, Italy
  • Padova, Veneto 35128, Italy
  • Setagaya, Tokyo 157-8535, Japan
  • Nijmegen, 6525 GA, Netherlands
  • Gdansk, 80-952, Poland
  • Olsztyn, 10-561, Poland
  • Moscow, 117997, Russian Federation
  • Nizhny Novgorod, 603136, Russian Federation
  • St. Petersburg, 197022, Russian Federation
  • Barcelona, 08035, Spain
  • Valencia, 46026, Spain
  • Bern, 3010, Switzerland
  • Newcastle Upon Tyne, Tyne And Wear NE1 4LP, United Kingdom
  • Birmingham, West Midlands B4 6NH, United Kingdom
  • Cardiff, CF14 4XW, United Kingdom
09

References and documents

Publications

  • Monagle P, Lensing AWA, Thelen K, Martinelli I, Male C, Santamaria A, Samochatova E, Kumar R, Holzhauer S, Saracco P, Simioni P, Robertson J, Grangl G, Halton J, Connor P, Young G, Molinari AC, Nowak-Gottl U, Kenet G, Kapsa S, Willmann S, Pap AF, Becka M, Twomey T, Beyer-Westendorf J, Prins MH, Kubitza D; EINSTEIN-Jr Phase 2 Investigators. Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studies. Lancet Haematol. 2019 Oct;6(10):e500-e509. doi: 10.1016/S2352-3026(19)30161-9. Epub 2019 Aug 13. PubMed 31420317 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2015 to primary completion in Apr 2017, 26 months.

Results were first posted in Jun 2018, 1 year 2 months after primary completion.

Of 27 phase 2 interventional studies under Venous Thromboembolism, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 50. This study's 26 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 24, 2014
First posted
Dec 5, 2014
StartActual
Jan 15, 2015
Primary completionActual
Apr 5, 2017
CompletionActual
Apr 5, 2017
Results first posted
Jun 13, 2018
Last update
Aug 21, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02309411
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Dec 5, 2014
Start date
Jan 15, 2015
Primary completion
Apr 5, 2017
Completion
Apr 5, 2017
Results posted
Jun 13, 2018
Last update
Aug 21, 2018

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rivaroxaban

Start the discussion